Higher or more frequent doses of Remicade may help reduce rheumatoid arthritis (RA) patients' joint pain and swelling, new research suggests. Most RA patients receive a 3-mg dose of the med every eight weeks. But a new study has found that increasing the dose to up to 10 mg or reducing the wait between doses decreases RA patients' joint pain and swelling by more than 20 percent. (Access to the full text of this article requires free registration to Medscape.)
Read moreAccording to a notice published today on the Food and Drug Administration website, FDA is investigating the possible association between... Read more »
Centocor, Inc. announced on August 14 that the FDA has expanded marketing approval for REMICADE® (infliximab) for the treatment of... Read more »
Over the past few years, studies have shown that people with rheumatoid arthritis and other rheumatic diseases have a higher risk of... Read more »
Vioxx made national headlines again in May with the news that incidents of cardiovascular problems begin much earlier than had previously... Read more »
During the busy summer travel season, I am reminded that planning a vacation is very similar to the way I approach accessing medical care.... Read more »
According to a new study, Crohn's disease patients who do not respond to treatment with Remicade (infliximab) can experience significant improvement... Read more »
Scientists say that the link between anti-tumor necrosis factor (TNF) drugs and cancer has been highlighted by one patient's unusual case. A... Read more »
Source: eOrthopod
Chronic pain is an increasing problem in the developed world, however, limited medical resources are causing longer than desirable waiting periods... Read more »